AbbVie’s ABBV-466 Shows Higher Endoscopic Remission Rates Than Monotherapies in Phase 2a Crohn’s Study

• AbbVie’s investigational dual-targeting therapy ABBV-466 outperformed either monotherapy in endoscopic remission in a Phase 2a trial for moderate to severe Crohn’s disease.
• Week 12 remission reached 30.2% with ABBV-466 versus 21.3% with risankizumab; trosunilimab achieved 18%.
• At Week 24, remission rose to 40.5% with ABBV-466 versus 22.4% with risankizumab; trosunilimab reached 20%.
• Serious adverse events occurred in 10.4% of ABBV-466 patients versus 9.6% with risankizumab; the trosunilimab rate was 9%.
• The open-label TARGET-CD trial enrolled 300 patients, with 75% having failed at least one advanced therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG74671) on October 19, 2026, and is solely responsible for the information contained therein.